Clinical trials: Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
Noninvasive Assessment of Metabolic Associated Fatty Liver Disease (MAFLD) in Chinese Population
Attenuation imaging (ATI) technology independently developed by Canon medical is a non-invasive examination technology for quantitative detection and analysis of liver steatosis.
- Trial name
- NCT04551716
- Where
- China
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Metabolic Dysfunction-associated Fatty Liver Disease, Cirrhosis
Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver…
- Trial name
- SMART (NCT06135584)
- Testing
- Pioglitazone metformin tablets, Other drugs, Drug-free
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
T2DM, MAFLD
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD
To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.
- Trial name
- NCT07289750
- Testing
- alogliptin and actoplus met, actoplus met
- Volunteers
- 80 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine